Franklin Resources Inc. Raises Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Franklin Resources Inc. lifted its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 52.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 123,101 shares of the company’s stock after acquiring an additional 42,315 shares during the quarter. Franklin Resources Inc.’s holdings in Nurix Therapeutics were worth $2,766,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Teachers Retirement System of The State of Kentucky raised its holdings in Nurix Therapeutics by 8.4% during the third quarter. Teachers Retirement System of The State of Kentucky now owns 30,024 shares of the company’s stock worth $675,000 after purchasing an additional 2,329 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Nurix Therapeutics by 9.6% in the third quarter. Geode Capital Management LLC now owns 1,448,040 shares of the company’s stock valued at $32,544,000 after buying an additional 126,306 shares in the last quarter. Barclays PLC boosted its position in shares of Nurix Therapeutics by 77.9% in the 3rd quarter. Barclays PLC now owns 128,344 shares of the company’s stock worth $2,884,000 after buying an additional 56,190 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Nurix Therapeutics in the 3rd quarter worth about $346,000. Finally, EP Wealth Advisors LLC acquired a new stake in Nurix Therapeutics in the 3rd quarter valued at about $240,000.

Nurix Therapeutics Stock Down 2.1 %

NASDAQ:NRIX opened at $19.57 on Thursday. The company has a market cap of $1.39 billion, a P/E ratio of -6.73 and a beta of 2.12. The firm’s 50 day moving average is $23.13 and its two-hundred day moving average is $22.40. Nurix Therapeutics, Inc. has a fifty-two week low of $7.65 and a fifty-two week high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX) last issued its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting the consensus estimate of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The business had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. Research analysts forecast that Nurix Therapeutics, Inc. will post -2.81 earnings per share for the current fiscal year.

Insider Transactions at Nurix Therapeutics

In related news, insider Christine Ring sold 3,290 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $25.00, for a total value of $82,250.00. Following the transaction, the insider now owns 24,592 shares in the company, valued at approximately $614,800. This trade represents a 11.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Houte Hans Van sold 3,546 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $24.28, for a total transaction of $86,096.88. Following the sale, the chief financial officer now owns 33,724 shares of the company’s stock, valued at approximately $818,818.72. This represents a 9.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,401 shares of company stock worth $437,453 in the last three months. 9.80% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have issued reports on NRIX shares. HC Wainwright lifted their target price on shares of Nurix Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Wednesday, December 11th. Jefferies Financial Group initiated coverage on Nurix Therapeutics in a research report on Friday, October 11th. They set a “buy” rating and a $41.00 price objective for the company. BMO Capital Markets assumed coverage on Nurix Therapeutics in a report on Friday, December 6th. They set an “outperform” rating and a $35.00 target price on the stock. UBS Group started coverage on Nurix Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Needham & Company LLC restated a “buy” rating and issued a $29.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, December 10th. One analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $30.35.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.